31 May 2019

Boustead Holdings

1Q19 Considered Inline

By Raymond Choo Ping Khoon I pkchoo@kenanga.com.my

1Q19 Core Net Loss (CNL) came in at RM22.4m compared to our full-year Net Profit forecast of RM76.8m. We consider the result to be within expectation due to the volatile quarterly results swinging back and forth between profitability and losses. Our SoP-derived target price is lowered from to RM1.50 to RM1.15, as we factored in lower TP for Pharmaniaga into our SoP calculation and attached a holding company discount of 20%. Maintain MP.

1Q19 Core Net Loss (CNL) came in at RM22.4m compared to our full-year Net Profit forecast of RM76.8m. We consider the result to be within expectation due to the volatile quarterly results swinging back and forth between profitability and losses. No dividend was declared as expected.

Results' highlights. QoQ, 1Q19 CNL narrowed to RM22.4m compared to 4Q18 core net loss of RM276m. 4Q18 core net loss excludes impairment of goodwill (RM106.2m), impairment of PPE and other receivables (RM107.5m), gains from sale of PPE (RM2.7m) and net fair value gain on investment properties (RM32.7m) largely due to higher contribution from Pharmaceutical and lower losses at Heavy Industries division. Pharmaceutical Division improved due to higher demand from government and private hospitals in Malaysia and Indonesia as well as lower finance cost. The lower deficit in Heavy Industries improved due to the high base in 4Q18 impacted by impairment of good will for BN Sand MHSA, revision in LCS project cost due to variation orders, share of loss in a joint venture company on provision for LAD, as well as impairment of aircraft.

YoY, 1Q19 recorded CNL of RM22.4m compared to a Core Net Profit of RM6m in the previous period, no thanks to losses at heavy industries and weaker contributions from Plantation and Property. Plantation was lower due to lower CPO (-19%) and PKO (-41%) prices. The Heavy Industries Division posted a deficit on the back of weaker results from its operating units. BNS incurred heavier losses for the quarter, mainly due to the revision of margins for the LCS project. In addition, ship repair activities were impacted by lack of projects. The Property segment was weaker due to weaker contributions from its various segments. The Hotel segment recorded an increased deficit, mainly due to lower occupancy and room rates. The Property investment segment also registered a higher deficit arising from start-up costs for the newly completed Nucleus Tower.

Outlook. The group is expected to continue seeing volatile quarterly results based on its historical volatile earnings trend. All in, we expect plantation earnings to anchor the bulk of earnings, and since 91% of its plantation estates are already matured, it hinges largely on CPO price movements of which the outlook over the short-term looks cloudy. The Heavy Industries division remains volatile with quarterly earnings oscillating between profits and losses. We expect the trading and manufacturing as well as pharmaceutical divisions to show pedestrian growth but deliver sustainable recurring incomes.

Maintain MP. Our SoP-derived target price is lowered from RM1.50 to RM1.15 implying 30.3x FY19E EPS (-1.0SD below 5-year forward historical mean), as we factor in lower TP for Pharmaniaga (from RM2.50 to RM2.35) into our SoP calculation and attached a holding company discount of 20%. Maintain MP.

MARKET PERFORM ↔

Price: RM1.11
Target Price: RM1.15



KLCI	1,636.50		
YTD KLCI chg	-3.2%		
YTD stock price chg	-21.3%		

Stock Information

Yes
BOUS MK Equity
2,250.0
2,027.0
2.52
1.11
329,676
25%
0.7

Major Shareholders

Lembaga Tabung Angkatan Tentera	59.5%
KWAP	10.1%
Employees Provident Fund	5.1%

Summary Earnings Table

FY Dec (RM'm)	2018A	2019E	2020E
Turnover	10,186	10,524	10,563
PBT	(387.9)	70.1	69.6
Net Profit (NP)	(469.2)	76.8	76.4
Core Net Profit/Loss	(286.5)	76.8	76.4
Earnings Revision	-	-	-
Core EPS (LPS) (sen)	(14.1)	3.8	3.8
EPS growth (%)	NM	NM	4.5
NDPS (sen)	5.0	3.0	3.0
BV/Share (RM)	2.65	2.66	2.67
PER (X)	NM	29.3	29.4
P/BV (X)	0.4	0.4	0.4
Net Gearing (x)	1.7	2.3	2.7
Dividend Yield (%)	4.5	2.7	2.7

31 May 2019

Result Highlight (Q-o-Q) FY Dec	2018	2018	2019	Y-o-Y	Q-o-Q
(RMm)	1Q	4Q	1Q	Chg (%)	Chg (%)
Revenue	2,300.3	3,024.7	2,506.7	(17.1)	9.0
Plantation	154.6	156.6	134.9	(13.9)	(12.7)
Heavy Industries	157.2	556.1	207.6	(62.7)	32.1
Property	108.2	167.4	110.3	(34.1)	1.9
Finance & Investment	49.1	57.2	52.5	(8.2)	6.9
Pharmaceutical	617.9	596.7	786.1	31.7	27.2
Trading & Industrial	1,213.3	1,490.7	1,215.3	(18.5)	0.2
EBIT	91.9	(367.1)	92.3	(125.1)	0.4
Plantation	8.8	1.8	(0.9)	(150.0)	(110.2)
Heavy Industries	7.2	(423.9)	(16.2)	(96.2)	(325.0)
Property	8.4	30.4	3.4	(88.8)	(59.5)
Finance & Investment	2.3	4.2	10.2	142.9	343.5
Pharmaceutical	34.0	19.5	37.5	92.3	10.3
Trading & Industrial	31.2	0.9	58.3	NM	86.9
Pretax profit	70.3	-542.4	51.5	(109.5)	(26.7)
Taxation	(32.2)	-22.6	-40.1	77.4	24.5
Minorities	(32.0)	110.0	(33.8)	(130.7)	5.6
Net profit	6.1	(455.0)	(22.4)	(95.1)	NM
EPS	0.3	(22.5)	(1.1)	(95.1)	NM
Ebit margin %					
Plantation	5.7	1.1	(0.7)		
Heavy Industries	4.6	(76.2)	(7.8)		
Property Development	7.8	18.2	3.1		
Finance & Investment	4.7	7.3	19.4		
Pharmaceutical	5.5	3.3	4.8		
Trading & manufacturing	2.6	0.1	4.8		
Effective tax rate	45.8	(4.2)	77.9		



31 May 2019

Stock Ratings are defined as follows:

Stock Recommendations

OUTPERFORM : A particular stock's Expected Total Return is MORE than 10%

MARKET PERFORM : A particular stock's Expected Total Return is WITHIN the range of -5% to 10%

UNDERPERFORM : A particular stock's Expected Total Return is LESS than -5%

Sector Recommendations***

OVERWEIGHT : A particular sector's Expected Total Return is MORE than 10%

NEUTRAL : A particular sector's Expected Total Return is WITHIN the range of -5% to 10%

UNDERWEIGHT : A particular sector's Expected Total Return is LESS than -5%

***Sector recommendations are defined based on market capitalisation weighted average expected total return for stocks under our coverage.

This document has been prepared for general circulation based on information obtained from sources believed to be reliable but we do not make any representations as to its accuracy or completeness. Any recommendation contained in this document does not have regard to the specific investment objectives, financial situation and the particular needs of any specific person who may read this document. This document is for the information of addressees only and is not to be taken in substitution for the exercise of judgement by addressees. Kenanga Investment Bank Berhad accepts no liability whatsoever for any direct or consequential loss arising from any use of this document or any solicitations of an offer to buy or sell any securities. Kenanga Investment Bank Berhad and its associates, their directors, and/or employees may have positions in, and may effect transactions in securities mentioned herein from time to time in the open market or otherwise, and may receive brokerage fees or act as principal or agent in dealings with respect to these companies.

Published and printed by:

KENANGA INVESTMENT BANK BERHAD (15678-H)

Level 17, Kenanga Tower, 237, Jalan Tun Razak, 50400 Kuala Lumpur, Malaysia

Telephone: (603) 2172 0880 Website: www.kenanga.com.my E-mail: research@kenanga.com.my

Chan Ken Yew Head of Research

